Multiple variant databases are creating competition among groups that disagree on how to advance the most scientifically robust and sustainable sharing model.
The study showed an overall benefit regardless of BRCA mutation or HRD status, but some analysts believe the FDA still might require a CDx for niraparib.
Although Tesaro used Myriad's BRCA and HRD tests to stratify patients, in the NOVA trial all recurrent ovarian cancer patients benefitted from niraparib.
Genetic testing can help guide prevention, establish a diagnosis, and choose treatment approaches for breast cancer, the Journal News says.
A retrospective review of panel sequencing data presented at the National Society of Genetic Counselors conference linked BRCA2 to primary brain cancer cases.
Health insurers and some clinicians spar over timing of genetic counseling for women with high breast cancer risk, NPR reports.
At HudsonAlpha's Genomic Medicine Conference University of North Carolina's Anya Prince discussed insurance coverage of genetic tests and preventive care.
A cancer patient with a rare BRCA1 variant seeks better data sharing, Newsweek reports.
A UK researcher has streamlined how women at her hospital with ovarian cancer seek genetic testing.
The researchers reported that BRCA2 was the most commonly mutated germline DNA-repair gene in their cohort.
In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.
The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.
Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.
Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.